CD44和转移抑制基因在声门上型喉癌及下咽癌原发灶及转移淋巴结的表达

目的比较声门上型喉癌及下咽癌原发灶与淋巴结转移癌细胞CD44和nm23-H1蛋白表达情况,进一步了解其转移特性。方法应用免疫组织化学方法和流式细胞检测方法观察了22例无淋巴转移的非转移组和41例病理证实有淋巴转移的声门上型喉癌、下咽癌患者的原发灶与淋巴转移灶中的CD44和nm23-H1表达情况。结果喉癌淋巴转移组CD44蛋白表达高于非转移组,nm23-H1,蛋白表达低于非转移组(P值均<0.05)。CD44、nm23-H1蛋白表达与声门上型喉癌、下咽癌的临床分期有关,和病理分级无关。原发灶肿瘤与淋巴转移灶肿瘤CD44和nm23-H1的表达阳性率分别为75.6%(31/41)、85.4%(35/41)和34.1%(14/41)、26.8%(11/41),差异无统计学意义(P>0.05)。原发灶肿瘤与淋巴转移灶肿瘤CD44和nm23-H1的平均荧光指数分别为(x-±s)1.27±0.18、1.33±0.16和1.11±0.19、1.08±0.15,差异无统计学意义(P>0.05)。结论声门上型喉癌及下咽癌原发灶与其转移淋巴结CD44、nm23-H1蛋白表达无明显差异,未能证明原发灶与其淋巴结转移灶肿瘤细胞转移潜能的差异,原发灶及其转移淋巴结的转移潜能比较还应从多靶点深入探讨。

Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer

OBJECTIVE: To study the metastasis feature of the primary and metastatic lymph node lesions in supraglottic or hypopharyngeal cancer. METHODS: The expression of CD44 and nm23-H1 in specimens from the primary and metastatic lymph node lesions of the 41 cases with supraglottic or hypopharyngeal cancer were studied with immunohistochemistry method and flow cytometry. RESULTS: No correlation was found between the expression of CD44, nm23-H1 and the tumor differentiation of the supraglottic or hypopharyngeal cancer, but their expression related with the chinical staging. The CD44 and nm23-H1 positive expression rates in the primary and metastatic lymph node lesions were 75.6% (31/41), 85.4% (35/41) and 34.1% (14/41), 26.8% (11/41) respectively (P >0.05). The average fluorescence index of CD44 and nm23-H1 in the primary and metastatic lymph node lesions were 1.27 +/- 0.18, 1.33 +/- 0.16 and 1.11 +/- 0.19, 1.08 +/- 0.15 (x +/- s) respectively (P >0.05). CONCLUSIONS: The expressions of CD44 and nm23-H1 in the metastatic lymph node tumor had no difference compared with that in primary tumor of the supraglottic or hypopharyngeal cancer. The difference of metastasis potentials between the primary and metastatic lymph node lesions in the same patient was not proved in this study and should be further investigated from multiple oncogens markers.